Empowered Patient Podcast

Karen Jagoda
  • 4.9 (18)
  • MEDICINE
  • UPDATED DAILY

Empowered Patient Podcast with Karen Jagoda is a window into the latest innovations in digital health, the changing dynamic between doctors and patients, and the emergence of precision medicine. The show covers such topics as aging in place, innovative uses for wearables and sensors, advances in clinical research, applied genetics, drug development, and challenges for connected health entrepreneurs.

  1. 1D AGO ·  BONUS

    Using Technology to Address Preventable Medical Harm with Joe Kiani Patient Safety Movement Foundation TRANSCRIPT

    Joe Kiani is Executive Chairman at Willow Laboratories and Founder of the Patient Safety Movement Foundation.   He makes the point that the vast majority of medical harm is avoidable through the implementation of evidence-based healthcare best practices. Technology, particularly AI and remote monitoring of data from medical devices, is crucial for creating predictive models that can alert clinicians to problems and identify root causes of medical errors. The goal is to unite all healthcare stakeholders to work collaboratively toward zero preventable deaths. Joe explains, "In the US, we lose about 200,000 people a year, and about 15 times that rate is the serious harm caused by medical errors. Worldwide, we think the number is close to three million. And the reason we call it preventable is that the vast majority could be eliminated if evidence-based practices were put in place. As you can imagine, people make mistakes, and there are a lot of medical errors that may not be preventable because there is an evidence-based practice in place to avoid them. But when it comes to things like hospital-acquired infection, VTE, sepsis, failure to rescue, CLATSI, there are known evidence-based practices that, if possible, put them in place, we might get to zero, and if not zero, we'd be pretty close to zero." "Well, honestly, all patients are at risk. If you want to focus on those most at risk, we've got to miss the ones that really go wrong. If we can imagine someone going in for a simple procedure, even a cosmetic one, like a hip replacement, and the procedure goes really well." "But while there's a catheter inside the artery, someone could walk in and, without cleaning their hands, touch the patient, the bacteria could enter the bloodstream and cause a serious infection. So really, you've got to create a culture of safety where you look for ways to mitigate people's mistakes, and those are what we call evidence-based practices. There are about 20 of them, starting with cultural patient safety, on the Patient Safety Movement Foundation website that people can freely download and implement, and therefore not get into these problems." #PatientSafetyMovementFoundation #PatientSafetyMovement #PatientSafety #HealthcareQuality #ZeroHarm #EvidenceBasedPractice #AIinHealthcare #ClinicalSafety #HospitalLeadership #MedTech #CultureOfSafety #PreventableHarm #FailureToRescue #Sepsis #VTE #PatientExperience #ClinicianBurnout willowlabs.ai psmf.org Listen to the podcast here

  2. 1D AGO

    Using Technology to Address Preventable Medical Harm with Joe Kiani Patient Safety Movement Foundation

    Joe Kiani is Executive Chairman at Willow Laboratories and Founder of the Patient Safety Movement Foundation.   He makes the point that the vast majority of medical harm is avoidable through the implementation of evidence-based healthcare best practices. Technology, particularly AI and remote monitoring of data from medical devices, is crucial for creating predictive models that can alert clinicians to problems and identify root causes of medical errors. The goal is to unite all healthcare stakeholders to work collaboratively toward zero preventable deaths. Joe explains, "In the US, we lose about 200,000 people a year, and about 15 times that rate is the serious harm caused by medical errors. Worldwide, we think the number is close to three million. And the reason we call it preventable is that the vast majority could be eliminated if evidence-based practices were put in place. As you can imagine, people make mistakes, and there are a lot of medical errors that may not be preventable because there is an evidence-based practice in place to avoid them. But when it comes to things like hospital-acquired infection, VTE, sepsis, failure to rescue, CLATSI, there are known evidence-based practices that, if possible, put them in place, we might get to zero, and if not zero, we'd be pretty close to zero." "Well, honestly, all patients are at risk. If you want to focus on those most at risk, we've got to miss the ones that really go wrong. If we can imagine someone going in for a simple procedure, even a cosmetic one, like a hip replacement, and the procedure goes really well." "But while there's a catheter inside the artery, someone could walk in and, without cleaning their hands, touch the patient, the bacteria could enter the bloodstream and cause a serious infection. So really, you've got to create a culture of safety where you look for ways to mitigate people's mistakes, and those are what we call evidence-based practices. There are about 20 of them, starting with cultural patient safety, on the Patient Safety Movement Foundation website that people can freely download and implement, and therefore not get into these problems." #PatientSafetyMovementFoundation #PatientSafetyMovement #PatientSafety #HealthcareQuality #ZeroHarm #EvidenceBasedPractice #AIinHealthcare #ClinicalSafety #HospitalLeadership #MedTech #CultureOfSafety #PreventableHarm #FailureToRescue #Sepsis #VTE #PatientExperience #ClinicianBurnout willowlabs.ai psmf.org Download the transcript here

    20 min

  3. 2D AGO ·  BONUS

    Digitizing Hospital Workflows Boosts Efficiency and Patient Outcomes with Sam Yeruva PyCube TRANSCRIPT

    Sam Yeruva is Founder and CEO of PyCube, a company that provides software solutions to US hospitals to digitize workflows and improve operational efficiency.  He points out that many hospital processes still rely on paper, which hinders the collection of data necessary for operational intelligence and forecasting. The key to success is breaking down data silos across departments to better track assets, samples, and pharmaceuticals, improving patient care, reducing clinician burnout, and driving cost savings.  Sam explains, "PyCube is a software solutions company serving US health systems across the Continental States. We provide solutions with digitized workflows around operational efficiency of the hospitals because there are a lot of things that happen in the hospitals.  A lot of things move, a lot of patients move, a lot of samples move, assets move. There are many moving parts in service environments, such as hospitals, which are well-equipped to care for patients. We help them to digitize those workflows and be more efficient. They're hearing hospitals actually running on thin margins. We assist the hospitals to utilize technology, to be more efficient, cut down the cost, improve revenue, and do what they're supposed to do normally, which they do really well, and take care of the patients. So that's where we try to assist hospitals in adopting technology, especially AI, as it is growing these days as well."   "Operational intelligence is a term coined to mean being smarter or doing things more smartly. You'll see when you go to a hospital, most of the things are still written on pen and paper. You don't get intelligence when you don't know where things are, and you don't know where data is not flowing. So we digitize those workflows so that, first of all, you use the right tools for digitizing the workflows. And then once you have that, we will instill some intelligence into the operation as well."  #PyCube #HealthcareInnovation #HospitalOperations #DigitalHealth #WorkflowAutomation #AIinHealthcare #OperationalIntelligence #PatientSafety #NurseWorkflow #InventoryManagement #HealthIT pycube.com Listen to the podcast here

  4. 2D AGO

    Digitizing Hospital Workflows Boosts Efficiency and Patient Outcomes with Sam Yeruva PyCube

    Sam Yeruva is Founder and CEO of PyCube, a company that provides software solutions to US hospitals to digitize workflows and improve operational efficiency.  He points out that many hospital processes still rely on paper, which hinders the collection of data necessary for operational intelligence and forecasting. The key to success is breaking down data silos across departments to better track assets, samples, and pharmaceuticals, improving patient care, reducing clinician burnout, and driving cost savings.  Sam explains, "PyCube is a software solutions company serving US health systems across the Continental States. We provide solutions with digitized workflows around operational efficiency of the hospitals because there are a lot of things that happen in the hospitals.  A lot of things move, a lot of patients move, a lot of samples move, assets move. There are many moving parts in service environments, such as hospitals, which are well-equipped to care for patients. We help them to digitize those workflows and be more efficient. They're hearing hospitals actually running on thin margins. We assist the hospitals to utilize technology, to be more efficient, cut down the cost, improve revenue, and do what they're supposed to do normally, which they do really well, and take care of the patients. So that's where we try to assist hospitals in adopting technology, especially AI, as it is growing these days as well."   "Operational intelligence is a term coined to mean being smarter or doing things more smartly. You'll see when you go to a hospital, most of the things are still written on pen and paper. You don't get intelligence when you don't know where things are, and you don't know where data is not flowing. So we digitize those workflows so that, first of all, you use the right tools for digitizing the workflows. And then once you have that, we will instill some intelligence into the operation as well."  #PyCube #HealthcareInnovation #HospitalOperations #DigitalHealth #WorkflowAutomation #AIinHealthcare #OperationalIntelligence #PatientSafety #NurseWorkflow #InventoryManagement #HealthIT pycube.com Download the transcript here

    19 min

  5. 2D AGO ·  BONUS

    Micro-Wearable Delivers Continuous Hydration Monitoring and Biomarker Insights with Professor Mark Kendall WearOptimo TRANSCRIPT

    Professor Mark Kendall, Founder and CEO of WearOptimo, is a pioneer in micro-wearable technology and highlights the limitations of current wearables that capture only basic signals.  The WearOptimo platform uses a skin patch with painless microelectrodes to measure a range of biomarkers in the interstitial fluid just beneath the skin surface.  The company's first product is a continuous hydration monitor designed to address the widespread and under-recognized health problems caused by dehydration due to lifestyle, disease, and working conditions. Mark explains, "We are all familiar with wearables. They're everywhere these days. And when we think about wearables, we're thinking about really basic signals, like an Apple Watch, an Oura ring, or a Whoop. And they're useful for really basic things. But the challenge is that there are all manner of really important health signals out there that today's wearables, like those, are just unable to reach. So, what we're looking to tackle with our technology, our powerful platform, the micro-wearable platform, is gaining access to those key signals that today's wearables are unable to reach and really opening up genuine healthcare."   "It feels just like a sticker, as I said, but the important piece is something that's microscopic. It's microelectrodes. It's an embodiment of a field called microneedles, and I'm a founder of that field. And those microelectrodes just pierce this tough outer dead layer of skin, called the stratum corneum, and reach this location just below the skin's surface. And in that location is a rich reservoir of signals. And we measure those with bio-impedance sweeps. We pull out electrical signals from the body, and use our bespoke, novel AI model to read those signals and give us distinct health outcomes." #WearOptimo #MicroWearable #WearableTech #HealthMonitoring #HydrationHealth # #MedTech #MicroneedleTechnology #PrecisionHealth #HealthcareInnovation #DigitalHealth #Wearables #Microneedles #HydrationMonitoring #Biomarkers #PatientSafety #PerioperativeCare #OccupationalHealth #MilitaryMedicine #AIinHealthcare #EdgeComputing #PreventiveCare wearoptimo.com Listen to the podcast here

  6. 2D AGO

    Micro-Wearable Delivers Continuous Hydration Monitoring and Biomarker Insights with Professor Mark Kendall WearOptimo

    Professor Mark Kendall, Founder and CEO of WearOptimo, is a pioneer in micro-wearable technology and highlights the limitations of current wearables that capture only basic signals.  The WearOptimo platform uses a skin patch with painless microelectrodes to measure a range of biomarkers in the interstitial fluid just beneath the skin surface.  The company's first product is a continuous hydration monitor designed to address the widespread and under-recognized health problems caused by dehydration due to lifestyle, disease, and working conditions. Mark explains, "We are all familiar with wearables. They're everywhere these days. And when we think about wearables, we're thinking about really basic signals, like an Apple Watch, an Oura ring, or a Whoop. And they're useful for really basic things. But the challenge is that there are all manner of really important health signals out there that today's wearables, like those, are just unable to reach. So, what we're looking to tackle with our technology, our powerful platform, the micro-wearable platform, is gaining access to those key signals that today's wearables are unable to reach and really opening up genuine healthcare."   "It feels just like a sticker, as I said, but the important piece is something that's microscopic. It's microelectrodes. It's an embodiment of a field called microneedles, and I'm a founder of that field. And those microelectrodes just pierce this tough outer dead layer of skin, called the stratum corneum, and reach this location just below the skin's surface. And in that location is a rich reservoir of signals. And we measure those with bio-impedance sweeps. We pull out electrical signals from the body, and use our bespoke, novel AI model to read those signals and give us distinct health outcomes." #WearOptimo #MicroWearable #WearableTech #HealthMonitoring #HydrationHealth # #MedTech #MicroneedleTechnology #PrecisionHealth #HealthcareInnovation #DigitalHealth #Wearables #Microneedles #HydrationMonitoring #Biomarkers #PatientSafety #PerioperativeCare #OccupationalHealth #MilitaryMedicine #AIinHealthcare #EdgeComputing #PreventiveCare wearoptimo.com Download the transcript here

    25 min

  7. 3D AGO ·  BONUS

    Patient-Centric Drug Development for Ovarian Cancer Targets Tumor Survival Pathway with Dr. Stella Vnook Kaida Biopharma TRANSCRIPT

    Dr. Stella Vnook, Co-Founder and Executive Chair of Kaida Biopharma, highlights the advantages for an early-stage biotech company to take a patient-centric perspective in drug development. She defines patient-centricity as focusing on whether a drug meaningfully improves a patient's life, which should influence decisions about trial design, endpoints, and side effects from the earliest stages. Kaida's work on a new treatment for ovarian cancer is designed to target tumor survival mechanisms and overcome treatment resistance, and has from the beginning taken into consideration the tolerability of treatments and the patient's quality of life. Stella explains, "We're so used to thinking drug-centric, and it's true that in the early stages of development, it's all about the molecule and the mechanism of action, and it's exciting to see how it works. But we really need to be thinking patient-centric because we will make decisions differently from the start. So it's not just about whether this drug works and how, but whether it meaningfully changes a patient's life. I think that's what patient-centric is or should be, because that would impact trial design, endpoints, and how we view tolerability or combination therapy."   "For ovarian cancer, women today may receive a variety of treatments. Now, let's talk about this for a second. It's the cancer that's usually diagnosed very late. That means the patient's tumor has already gone into the lymph nodes, and it's what we call a stage three PO4. The patients after surgery receive a variety of drugs such as platinum therapies or PARP, but they still may relapse, and they may become resistant to the therapy. Now, that initial therapy has probably had significant toxicity. Because they've become resistant to the therapy they received, now they have limited options. So fortunately, there are drugs that potentially could be eligible for FRA positive. There's been a lot of news about ELAHERE, which is great, but it's only 25% of the population, and many patients may never qualify for this treatment. So that's where Kaida comes in, because we're focusing on 80% of the population."  "Actually, the name Kaida is a dragon that eats its own tail. So that talks about the mechanism of action we've discussed: resistance. What we do is when the treatment has been given, it supports cell survival and actually eliminates the tumor's ability to replicate, which is called proliferation, causing it to destroy itself, which is called apoptosis. So in essence, the tumor disrupts itself because we're cutting off its support system." #Kaida #OvarianCancer #PatientCentric #OncologyInnovation #ProlactinReceptor #DrugDevelopment #AIinHealthcare #RealWorldEvidence #TolerabilityMatters #KaidaBiopharma #CancerCare Kaida-biopharma.com Listen to the podcast here

  8. 3D AGO

    Patient-Centric Drug Development for Ovarian Cancer Targets Tumor Survival Pathway with Dr. Stella Vnook Kaida Biopharma

    Dr. Stella Vnook, Co-Founder and Executive Chair of Kaida Biopharma, highlights the advantages for an early-stage biotech company to take a patient-centric perspective in drug development. She defines patient-centricity as focusing on whether a drug meaningfully improves a patient's life, which should influence decisions about trial design, endpoints, and side effects from the earliest stages. Kaida's work on a new treatment for ovarian cancer is designed to target tumor survival mechanisms and overcome treatment resistance, and has from the beginning taken into consideration the tolerability of treatments and the patient's quality of life. Stella explains, "We're so used to thinking drug-centric, and it's true that in the early stages of development, it's all about the molecule and the mechanism of action, and it's exciting to see how it works. But we really need to be thinking patient-centric because we will make decisions differently from the start. So it's not just about whether this drug works and how, but whether it meaningfully changes a patient's life. I think that's what patient-centric is or should be, because that would impact trial design, endpoints, and how we view tolerability or combination therapy."   "For ovarian cancer, women today may receive a variety of treatments. Now, let's talk about this for a second. It's the cancer that's usually diagnosed very late. That means the patient's tumor has already gone into the lymph nodes, and it's what we call a stage three PO4. The patients after surgery receive a variety of drugs such as platinum therapies or PARP, but they still may relapse, and they may become resistant to the therapy. Now, that initial therapy has probably had significant toxicity. Because they've become resistant to the therapy they received, now they have limited options. So fortunately, there are drugs that potentially could be eligible for FRA positive. There's been a lot of news about ELAHERE, which is great, but it's only 25% of the population, and many patients may never qualify for this treatment. So that's where Kaida comes in, because we're focusing on 80% of the population."  "Actually, the name Kaida is a dragon that eats its own tail. So that talks about the mechanism of action we've discussed: resistance. What we do is when the treatment has been given, it supports cell survival and actually eliminates the tumor's ability to replicate, which is called proliferation, causing it to destroy itself, which is called apoptosis. So in essence, the tumor disrupts itself because we're cutting off its support system." #Kaida #OvarianCancer #PatientCentric #OncologyInnovation #ProlactinReceptor #DrugDevelopment #AIinHealthcare #RealWorldEvidence #TolerabilityMatters #KaidaBiopharma #CancerCare Kaida-biopharma.com Download the transcript here

    19 min
See All (2K)

4.9
out of 5
18 Ratings

About

Empowered Patient Podcast with Karen Jagoda is a window into the latest innovations in digital health, the changing dynamic between doctors and patients, and the emergence of precision medicine. The show covers such topics as aging in place, innovative uses for wearables and sensors, advances in clinical research, applied genetics, drug development, and challenges for connected health entrepreneurs.

Information

You Might Also Like